AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26341547
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 200 μg beclomethasone dipropionate (BDP) in forward leaning posture
Trial: 24083590
Drug: HHPG‐19K 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HHPG‐19K 60 μg/kg/day
Trial: 24083590
Drug: HHPG‐19K 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HHPG‐19K 100 μg/kg/day
Trial: 24083590
Drug: HHPG‐19K 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HHPG‐19K 200 μg/kg/day
Trial: 24083590
Drug: Filgrastim (G‐CSF)
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Filgrastim (G‐CSF) 5 μg/kg/day
Trial: 21982667
Drug: Prasugrel 10
RxNorm normalized name: prasugrel 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 10 mg/day
Trial: 21982667
Drug: High-dose clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose clopidogrel 150 mg/day
Trial: 21511219
Drug: Prasugrel 10
RxNorm normalized name: prasugrel 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 10 mg/day (in carriers of CYP2C19*2)
Trial: 21511219
Drug: High-dose clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose clopidogrel 150 mg/day (in carriers of CYP2C19*2)
Trial: 21511219
Drug: Prasugrel 10
RxNorm normalized name: prasugrel 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 10 mg/day (in noncarriers of CYP2C19*2)
Trial: 21511219
Drug: High-dose clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose clopidogrel 150 mg/day (in noncarriers of CYP2C19*2)
Trial: 11831540
Drug: Retigabine (200,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retigabine (200, 400, 500, and 600 mg per day fixed doses; 700 mg per day titrated doses)
Trial: 11831540
Drug: Retigabine (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retigabine (titrated doses up to 700 mg per day)
Trial: 11831540
Drug: Retigabine (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retigabine (multiple doses)
Trial: 9702467
Drug: Metformin (850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (850 mg bd)
Trial: 2405291
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous immunoglobulin (IVIg)
Trial: 20939913
Drug: Program led
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Program led by a clinical pharmacist trained in motivational interviewing‐based behavioral counseling approaches and authorized to make BP medication changes
Trial: 18632838
Drug: Headgear (HG)
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Hydro-Tussin HG]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Headgear (HG) treatment initiated immediately
Trial: 12755838
Drug: Post-operative transarterial
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-operative transarterial chemotherapy
Trial: 9065253
Drug: Daily changing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily changing of ventilation tubes
Trial: 9065253
Drug: Infusion sets
RxNorm normalized name: INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion sets changed daily
Trial: 9065253
Drug: Drugs for
RxNorm normalized name: DRUGS FOR CONSTIPATION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs for the prevention of stress ulcers
Trial: 6148312
Drug: Bopindolol (1-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bopindolol (1-4 mg once daily)
Trial: 6148312
Drug: Propranolol (40-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40-120 mg t.i.d.)
Trial: 23324133
Drug: Concurrent medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent medical and chiropractic care
Trial: 27644138
Drug: ε-caprolactam concentration
RxNorm normalized name: N-dodecyl-.epsilon.-caprolactam
DrugBank: Laurocapram (DB17308)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ε-caprolactam concentration of 0.05 mg/m³
Trial: 27644138
Drug: ε-caprolactam concentration
RxNorm normalized name: N-dodecyl-.epsilon.-caprolactam
DrugBank: Laurocapram (DB17308)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ε-caprolactam concentration of 0.5 mg/m³
Trial: 27644138
Drug: ε-caprolactam concentration
RxNorm normalized name: N-dodecyl-.epsilon.-caprolactam
DrugBank: Laurocapram (DB17308)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ε-caprolactam concentration of 5.0 mg/m³
Trial: 27644138
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition (0.0 mg/m³)
Trial: 19123874
Drug: Shirodhara treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shirodhara treatment
Trial: 15927409
Drug: Immediate concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate concurrent chemoradiation (cisplatin-based) with short overall treatment time (completed within 5 days of plan)
Trial: 15927409
Drug: Immediate concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate concurrent chemoradiation (cisplatin-based) with prolonged treatment time (protocol violation)
Trial: 15927409
Drug: Treatment time
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment time as a continuous variable
Trial: 15927409
Drug: Immediate concurrent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate concurrent chemoradiation (cisplatin-based)
Trial: 15478385
Drug: Fluticasone propionate,
RxNorm normalized name: fluticasone propionate, micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate, 2000 microg/d via a 750-mL primed spacer for 2 weeks
Trial: 9247510
Drug: 400 IU
RxNorm normalized name: Vitamin D 400 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 IU of vitamin E, 500 mg of vitamin C, 12 mg of beta-carotene (mid-dose)
Trial: 9247510
Drug: 800 IU
RxNorm normalized name: Vitamin E 800 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 IU of vitamin E, 1,000 mg of vitamin C, 24 mg of beta-carotene (high dose)
Trial: 3552460
Drug: 10/10/10 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10/10/10 micrograms HA formulation
Trial: 3552460
Drug: Monovalent A/Singapore/6/86-like
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent A/Singapore/6/86-like vaccine
Trial: 3552460
Drug: Trivalent A/Mississippi,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent A/Mississippi, A/Chile, B/Ann Arbor influenza vaccine
Trial: 3552460
Drug: A/Singapore vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A/Singapore vaccine
Trial: 27840374
Drug: α-lipoic acid
RxNorm normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-lipoic acid (LA) treatment
Trial: 18553032
Drug: Ropivacaine 0.125%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.125% (15 ml)
Trial: 18553032
Drug: Ropivacaine 0.0625%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.0625% plus 75 microg clonidine (15 ml)
Trial: 16651056
Drug: Low-dose warfarin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose warfarin (mean INR 1.4, goal INR <2.0)
Trial: 12816770
Drug: L-MUFA (7.8%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-MUFA (7.8% of energy from MUFAs)
Trial: 10853566
Drug: Bupivacaine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine administered preoperatively
Trial: 7756096
Drug: Mizolastine 10
RxNorm normalized name: mizolastine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizolastine 10 mg once daily for 8 days
Trial: 7756096
Drug: Lorazepam 2
RxNorm normalized name: lorazepam 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam 2 mg single dose
Trial: 2312774
Drug: Metoprolol CR/ZOK
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol CR/ZOK 100-200 mg daily
Trial: 31989459
Drug: 10% dextrose
RxNorm normalized name: Aminosyn II 4.25% in 10% Dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% dextrose solution
Trial: 29390915
Drug: Infusion site
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion site failure detection algorithm
Trial: 23987833
Drug: Trabectedin as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin as second-line treatment (24-hour infusion every 3 weeks)
Trial: 22534669
Drug: Pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/m²) + Cisplatin (75 mg/m²) followed by Gefitinib (250 mg/d)
Trial: 22534669
Drug: Pemetrexed (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed (500 mg/m²) + Cisplatin (75 mg/m²) followed by Pemetrexed (500 mg/m²)
Trial: 15671124
Drug: Citalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citalopram (20 mg on days 1-8, 40 mg on days 8-15)
Trial: 15671124
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg on days 1-8, 100 mg on days 8-15)
Trial: 10494365
Drug: Metoclopramide (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (0.3 mg x kg‐1)
Trial: 10494365
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dimenhydrinate (1 mg x kg‐1) and metoclopramide (0.3 mg x kg‐1)
Trial: 9005795
Drug: Ofloxacin 200
RxNorm normalized name: ofloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 200 mg once a day for medium urinary tract infections
Trial: 9005795
Drug: Ofloxacin 100
RxNorm normalized name: ofloxacin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 100 mg twice a day for 3 to 7 days for severe lower urinary tract infections
Trial: 9005795
Drug: Ofloxacin 200
RxNorm normalized name: ofloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 200 mg twice a day for 7 to 10 days for severe upper urinary tract infections
Trial: 9005795
Drug: Ofloxacin 50
RxNorm normalized name: levofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 50 mg once a day for 6 months for frequent acute recurring infections
Trial: 6788406
Drug: Ketotifen (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (1 mg twice daily, orally)
Trial: 6788406
Drug: Disodium cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium cromoglycate (inhalation of 20 mg, four times daily)
Trial: 6366148
Drug: Four-drug program
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-drug program (cyclophosphamide, vincristine, methotrexate, prednisone [COMP])
Trial: 6366148
Drug: 10-drug program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-drug program (LSA2-L2 modified)
Trial: 22975616
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (5 cycles of fluorouracil and leucovorin)
Trial: 22975616
Drug: Chemoradiation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiation therapy (1 cycle of FL, then 45 Gy radiation concurrently with 2 cycles of FL, followed by 2 cycles of FL)
Trial: 19460762
Drug: Comfrey root
RxNorm normalized name: COMFREY ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comfrey root extract ointment (4 g per application, three times a day)
Trial: 19460762
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment (4 g per application, three times a day)
Trial: 19460762
Drug: Comfrey root
RxNorm normalized name: COMFREY ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comfrey root extract ointment
Trial: 10025472
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (100 mg daily) and Vitamin C (500 mg daily) for 15 weeks
Trial: 2347518
Drug: Aspirin at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin at very ultra low dosage
Trial: 373517
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nebulized atropine sulfate and isoproterenol
Trial: 25746779
Drug: Low-dose computed
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose computed tomography
Trial: 23904337
Drug: Sublingual lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual lorazepam (0.1 mg/kg, n = 234)
Trial: 23904337
Drug: Intrarectal diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrarectal diazepam (0.5 mg/kg, n = 202)
Trial: 21903893
Drug: Armodafinil (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Armodafinil (titrated to 250 mg daily in the morning)
Trial: 19221726
Drug: Quercetin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin (500 mg, 3 times a day for 7 days)
Trial: 17591036
Drug: Probiotics (Enterococcus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (Enterococcus faecalis T‐110, Clostridium butyricum TO‐A, and Bacillus mesentericus TO‐A) administered perioperatively, starting immediately after admission, 3 to 15 days before the operation, and continued until hospital discharge.
Trial: 15040824
Drug: Calcium and
RxNorm normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium and Vitamin D Program (1000 mg of elemental calcium as calcium carbonate and 400 IU of vitamin D3 daily)
Trial: 10632537
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of styrene maleic acid neocarzinostatin in 4 ml of Lipiodol (Group A)
Trial: 10632537
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of epirubicin in 4 ml of Lipiodol (Group B)
Trial: 8211540
Drug: Enoxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxacin (400 mg oral)
Trial: 8211540
Drug: Ceftriaxone (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (250 mg intramuscular)
Trial: 3546170
Drug: Non-living promastigote
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-living promastigote vaccine
Trial: 31682572
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavioral therapy (ICBT) blended with weekly real-time therapist chat sessions for 8 weeks
Trial: 23808298
Drug: Ivabradine (dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine (dose titrated during 2 weeks)
Trial: 23808298
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with ivabradine + atenolol (in half doses)
Trial: 23808298
Drug: Ivabradine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine (15 mg/day)
Trial: 21861038
Drug: Transition to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transition to low-molecular-weight heparin (LMWH) - enoxaparin: 1 mg/kg 2x/day before ablation, and 0.5 mg/kg 2x/day after ablation
Trial: 21861038
Drug: Maintenance of
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance of warfarin with therapeutic INR (between 2.0 and 3.0)
Trial: 18444883
Drug: VCL‐CB01 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VCL‐CB01 vaccine (1- or 5-mg doses) administered on a 0-, 2-, and 8-week schedule
Trial: 18444883
Drug: VCL‐CB01 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VCL‐CB01 vaccine (5-mg doses) administered on a 0-, 3-, 7-, and 28-day schedule
Trial: 11269896
Drug: Local conjunctival
RxNorm normalized name: Sus scrofa conjunctiva preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local conjunctival immunotherapy (LCIT) with standardized dermatophagoides pteronyssinus (Dp) extracts, administered daily for 6 months at increasing concentrations starting from 10 AU/ml to a maintenance dose of 1,000 AU/ml.
Trial: 11269896
Drug: Placebo treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment, administered daily for 6 months.
Trial: 9109894
Drug: 16 mg/d
RxNorm normalized name: futibatinib 16 mg/day (4 mg x 4) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg/d tiagabine
Trial: 9109894
Drug: 32 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32 mg/d tiagabine
Trial: 9109894
Drug: 56 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 56 mg/d tiagabine
Trial: 3084705
Drug: Multiple-monitored electroconvulsive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-monitored electroconvulsive therapy (MMECT)
Trial: 3084705
Drug: Conventional electroconvulsive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional electroconvulsive therapy (CECT)
Trial: 30892820
Drug: NAFLD defined
RxNorm normalized name: refined almond oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAFLD defined using a liver‐spleen ratio (L/S ratio) ≤1.1 on unenhanced abdominal CT scanning
Trial: 30892820
Drug: L/S ratio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L/S ratio ≤1.1
Trial: 30630798
Drug: Spinal-epidural anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal-epidural anesthesia with intravenous injection of dexmedetomidine
Trial: 23525418
Drug: Warfarin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin therapy (experienced vs naïve)
Trial: 20597245
Drug: Nicotine gum
RxNorm normalized name: Equate Nicotine Gum 4mg Starter Kit
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine gum (4 mg, one stick per hour)
Trial: 19075486
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (controls, 61 patients)
Trial: 11099628
Drug: Cisapride (0.80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (0.80 mg/kg/day for group 1 and 2; 0.72 mg/kg/day for group 3)
Trial: 2830968
Drug: Thymosin fraction
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thymosin fraction V (60 mg/m2 s.c. twice weekly) during induction chemotherapy and radiation therapy
Trial: 31515562
Drug: Serum neurofilament
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum neurofilament light chain (sNfL) levels measured using an ultrasensitive single‐molecule array assay (Simoa)
Trial: 28463718
Drug: Computer-assisted cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-assisted cognitive remediation (CACR) therapy
Trial: 23706259
Drug: Antibiotic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic group (flomoxef sodium every 12 hours for 3 days)
Trial: 23706259
Drug: Non‐postoperative antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non‐postoperative antibiotic group
Trial: 21744744
Drug: Myo-inositol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myo-inositol (2 g) + Folic acid (200 microg)
Trial: 11559340
Drug: Topical nasal
RxNorm normalized name: Nasal Inhalant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nasal drops dyed with methylene blue (0.1% v/v)
Trial: 11559340
Drug: Topical aqueous
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical aqueous sprays dyed with methylene blue (0.1% v/v)
Trial: 9427455
Drug: Acellular pertussis
RxNorm normalized name: Acellular pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis vaccine (Pa)
Trial: 9427455
Drug: Whole cell
RxNorm normalized name: pertussis, whole cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole cell pertussis vaccine (Pw)
Trial: 7705531
Drug: Low-dose monophasic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose monophasic pill
Trial: 7705531
Drug: High-dose monophasic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose monophasic pill
Trial: 7705531
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy (expectant management)
Trial: 2884705
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg tulobuterol/day
Trial: 2884705
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg fenoterol/day
Trial: 2884705
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment / pretreatment with oral fenoterol
Trial: 2884705
Drug: Tulobuterol and
RxNorm normalized name: tulobuterol
DrugBank: Tulobuterol (DB12248)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tulobuterol and fenoterol treatment
Trial: 30123970
Drug: Ruxolitinib 15
RxNorm normalized name: ruxolitinib 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib 15 mg BID plus regorafenib 160 mg QD
Trial: 30123970
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus regorafenib 160 mg QD
Trial: 24771634
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g ceftriaxone (IV infusion every 12 hours)
Trial: 24771634
Drug: Placebo (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (IV infusion every 12 hours)
Trial: 24771634
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g ceftriaxone twice (IV infusion every 12 hours)